Evidence map›Paper›PMID 38226470›Full record

ArticleHypertension (Dallas, Tex. : 1979)2024

Asymmetric Dimethylarginine Enables Depolarizing Spikes and Vasospasm in Mesenteric and Coronary Resistance Arteries.

Yu Y Hanson Ng, Kim A Dora, Hamish A L Lemmey, JinHeng Lin, James Alden, Lillian Wallis, Lucy Donovan, Oliver Shorthose, Fiona C Leiper, James Leiper and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Hypertension (Dallas, Tex. : 1979), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Yu Y Hanson NgDepartment of Pharmacology, University of Oxford, United Kingdom (Y.Y.H.N., K.A.D., H.A.L.L., J. Lin, J.A., L.W., LD., O.S., C.J.G.).ORCID 0000-0003-3260-424X
Kim A DoraDepartment of Pharmacology, University of Oxford, United Kingdom (Y.Y.H.N., K.A.D., H.A.L.L., J. Lin, J.A., L.W., LD., O.S., C.J.G.).ORCID 0000-0002-8014-2775
Hamish A L LemmeyDepartment of Pharmacology, University of Oxford, United Kingdom (Y.Y.H.N., K.A.D., H.A.L.L., J. Lin, J.A., L.W., LD., O.S., C.J.G.).ORCID 0000-0002-7679-9125
JinHeng LinDepartment of Pharmacology, University of Oxford, United Kingdom (Y.Y.H.N., K.A.D., H.A.L.L., J. Lin, J.A., L.W., LD., O.S., C.J.G.).ORCID 0000-0001-6424-204X
James AldenDepartment of Pharmacology, University of Oxford, United Kingdom (Y.Y.H.N., K.A.D., H.A.L.L., J. Lin, J.A., L.W., LD., O.S., C.J.G.).
Lillian WallisDepartment of Pharmacology, University of Oxford, United Kingdom (Y.Y.H.N., K.A.D., H.A.L.L., J. Lin, J.A., L.W., LD., O.S., C.J.G.).
Lucy DonovanDepartment of Pharmacology, University of Oxford, United Kingdom (Y.Y.H.N., K.A.D., H.A.L.L., J. Lin, J.A., L.W., LD., O.S., C.J.G.).ORCID 0000-0002-8667-3032
Oliver ShorthoseDepartment of Pharmacology, University of Oxford, United Kingdom (Y.Y.H.N., K.A.D., H.A.L.L., J. Lin, J.A., L.W., LD., O.S., C.J.G.).
Fiona C LeiperInstitute of Cardiovascular and Medical Sciences, College of Medicine, Veterinary, and Life Sciences, University of Glasgow, United Kingdom (F.C.L., J. Leiper).ORCID 0000-0001-6681-681X
James LeiperInstitute of Cardiovascular and Medical Sciences, College of Medicine, Veterinary, and Life Sciences, University of Glasgow, United Kingdom (F.C.L., J. Leiper).ORCID 0000-0003-4656-519X
Christopher J GarlandDepartment of Pharmacology, University of Oxford, United Kingdom (Y.Y.H.N., K.A.D., H.A.L.L., J. Lin, J.A., L.W., LD., O.S., C.J.G.).ORCID 0000-0003-0848-6044
Anna Needs Neuroblastoma Answers · USCardiovascular Institute of the South · USJames Cropper (United Kingdom) · GBOxford Instruments (United Kingdom) · GBUniversity of Oxford · GB

Funding

British Heart Foundation PG/19/36/34396British Heart Foundation PG/20/10260British Heart Foundation PG/23/11496
6 · The paper itself

Abstract

backgroundIncreased vasoreactivity due to reduced endothelial NO bioavailability is an underlying feature of cardiovascular disease, including hypertension. In small resistance arteries, declining NO enhances vascular smooth muscle (VSM) reactivity partly by enabling rapid depolarizing Ca

methodsRat isolated small mesenteric arteries and myogenic rat-isolated intraseptal coronary arteries (RCA) were studied using myography, VSM intracellular recording, Ca

resultsADMA enhanced rat-isolated small mesenteric arteries vasoreactivity to the α

conclusionsADMA increases VSM electrical excitability enhancing vasoreactivity. Endothelial DDAH1 reduces this effect, and low levels of DDAH1 in RCAs may render them susceptible to endothelial dysfunction contributing to vasospasm, changes opposed by L-arginine.

Indexed as

Cardiovascular DiseasesAmidohydrolasesAnimalsArginineCoronary VesselsNitric OxideNitric Oxide SynthaseRatsAmidohydrolasesArginineNitric OxideNitric Oxide SynthaseN,N-dimethylargininecardiovascular diseasescoronary arteryendotheliumhypertensionischemic heart disease

Identifiers

PMID38226470
PMCPMC10956675
OpenAlexW4390913628

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.